RT Journal Article
SR Electronic
T1 Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2203
OP 2207
DO 10.21873/anticanres.14996
VO 41
IS 4
A1 NIISATO, YUSUKE
A1 MORIWAKI, TOSHIKAZU
A1 FUKUOKA, SHOTA
A1 MASUISHI, TOSHIKI
A1 TAKASHIMA, ATSUO
A1 KUMEKAWA, YOSUKE
A1 KAJIWARA, TAKESHI
A1 YAMAZAKI, KENTARO
A1 ESAKI, TAITO
A1 MAKIYAMA, AKITAKA
A1 DENDA, TADAMICHI
A1 HATACHI, YUKIMASA
A1 SUTO, TAKESHI
A1 SUGIMOTO, NAOTOSHI
A1 SHIMADA, YASUHIRO
YR 2021
UL http://ar.iiarjournals.org/content/41/4/2203.abstract
AB Background/Aim: In later-line treatment of metastatic colorectal cancer (mCRC), trifluridine/tipiracil is often selected because regorafenib is difficult to use in patients with comorbidities such as thrombosis, hemorrhage, or cardiac events. However, the safety and efficacy of trifluridine/tipiracil in these patients is not clear. Patients and Methods: The clinical outcomes of trifluridine/tipiracil were retrospectively investigated in patients who were ineligible for regorafenib because of comorbidities. Results: Among the 27 patients who received trifluridine/tipiracil, many had comorbidities of deep venous thrombosis or hemorrhage. The median overall survival was 12.4 months, and the median progression-free survival was 2.8 months. The median overall survival was 7.7 months in 19 patients without subsequent regorafenib. Grade 3 or higher toxicities were found in 51% of patients. No treatment discontinuation because of comorbidities was observed. Conclusion: Trifluridine/tipiracil can be safely administered while maintaining efficacy in patients who were ineligible for regorafenib.